CONSHOHOCKEN, Pa., June 19, 2013 (GLOBE NEWSWIRE) -- CardioNet, Inc. (Nasdaq:BEAT) ("CardioNet"), the leading wireless medical technology company focused on diagnosing and monitoring cardiac arrhythmias, announced today the launch of the MCOTos 2:1 device, providing both MCOTTM and wEvent monitoring capability in a single device. This added feature provides increased flexibility and convenience to both physicians and patients.
Joseph Capper, President and Chief Executive Officer of CardioNet, commented: "As part of our CardioNet Comprehensive strategy, we continue to develop solutions designed to serve all of the cardiac monitoring needs of our patients and practices. Consistent with this strategy, we are pleased to announce the latest addition to our cardiac monitoring device line-up, the MCOTos 2:1. With this device, we are able to offer either MCOTTM or wEvent monitoring, on demand, in the convenience of a single device. By combining these two life-saving technologies in one system, we are able to monitor patients more effectively, while providing increased efficiency and ease of use to our physicians. As evidenced with this latest introduction, we remain committed to providing our customers the best wireless cardiac monitoring solutions on the market."
CardioNet is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual's health. CardioNet's initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient TelemetryTM (MCOTTM). More information can be found at http://www.cardionet.com.
Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our expectations regarding the effect of the MCOTos 2:1 device on the company's operating results. These statements may be identified by words such as "expect," "anticipate," "estimate," "intend," "plan," "believe," "promises" and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of changes in health care legislation, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, litigation success, our ability to successfully create a new holding company structure and to anticipate the benefits of such structure. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CardioNet, Inc. Heather C. Getz Investor Relations 800-908-7103